EGFR and non-small cell lung carcinoma: EGFR tyrosine kinase inhibitors (EGFR-TKIs) provide a survival benefit in EGFR-mutant non-small-cell lung cancer (NSCLC) (Ohashi et al. 2013; Soria et al. 2018).